Since the very beginning of his path to and through the White House, Donald Trump has slandered undocumented people migrating…
An Ontario regulatory organization for pharmacists is cracking down on a grassroots harm reductionist for his naloxone distribution efforts—even though…
OxyContin got a makeover in 2010. That year, the Food and Drug Administration approved a new version of the opioid,…
The battle to hold corporations accountable for their involvement in fueling chaotic opioid use and overdose deaths in vulnerable communities…
If it were up to me, it’s unlikely I would be sitting down to write about my life with chronic…
On May 8, pharmaceutical company Gilead quietly announced that it will relinquish its exclusive patent on Truvada for HIV pre-exposure…
The fight for universal access to PrEP medication for HIV prevention was picked up by Vermont Senator and presidential hopeful…
It's been less than two weeks since the US Department of Justice joined a string of lawsuits against Indivior—the maker…
On April 16, the Drug Enforcement Administration (DEA) launched its latest punishment-driven, treatment-inflected response to the opioid-involved overdose crisis in…
In the lucrative but hit-and-miss opioid use disorder treatment field, buprenorphine is one medication that has demonstrated outstanding efficacy. It’s…